<SEC-DOCUMENT>0001157523-23-000914.txt : 20230526
<SEC-HEADER>0001157523-23-000914.hdr.sgml : 20230526
<ACCEPTANCE-DATETIME>20230526060012
ACCESSION NUMBER:		0001157523-23-000914
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230526
FILED AS OF DATE:		20230526
DATE AS OF CHANGE:		20230526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		23962856

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a53407863.htm
<DESCRIPTION>INNATE PHARMA S.A. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <div>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">&#160;SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.9pt; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
      EXCHANGE ACT OF 1934</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Date of report: For the month of May 2023</div>
    <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Commission File Number: 001-39084</div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">Innate Pharma S.A.</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt;">&#160;(Translation of registrant's name into English)</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-weight: bold;">Innate Pharma S.A.</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-weight: bold;">&#160;117 Avenue de Luminy&#8212;BP 30191</div>
    <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt; font-weight: bold;">&#160;13009 Marseille, France</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 2.3pt; font-weight: bold;">&#160;+ 33 (0) 4 30 30 30</div>
    <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt;">&#160;(Address of principal executive office)</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </div>
    <div style="font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Form 20-F [ X ]<font class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160; </font>Form 40-F [ ]</div>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [&#160; ]</div>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [&#160; ]</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">INCORPORATION BY REFERENCE</div>
    </div>
    <div>
      <div>&#160;</div>
      <div>This Report on Form&#160;6-K&#160;[and Exhibit 99.1 to this Report on Form&#160;6-K]&#160;shall be deemed to be incorporated by reference into the registration statement on
        Form&#160;F-3&#160;(File&#160;No.&#160;333-252074)&#160;of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or
        reports subsequently filed or furnished.</div>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-weight: bold;">EXHIBIT INDEX</div>
    <div>&#160; <br>
    </div>
    <div><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit</u></font><font class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-weight: bold; font-family: 'Times New Roman',Times,serif;"><u>Description</u></font></div>
    <div><br>
    </div>
    <div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <div><a href="a53407863ex99_1.htm">99.1</a>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [<a href="a53407863ex99_1.htm">Press Release dated May 26, 2023</a>]</div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div style="margin-right: 14.85pt; margin-left: 5.55pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
      be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z6943d1e7fbfd48f0829a2e19b84b5d96">

          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 6%; font-weight: bold;" rowspan="1" colspan="2">
              <div>INNATE PHARMA S.A.</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 6%;">
              <div>&#160;</div>
            </td>
            <td style="width: 39%;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 6%;">
              <div>&#160;</div>
            </td>
            <td style="width: 39%;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; font-family: 'Times New Roman',Times,serif; text-align: left; vertical-align: bottom;">
              <div>Date: May 26, 2023</div>
            </td>
            <td style="width: 6%; font-family: 'Times New Roman',Times,serif; text-align: left; vertical-align: bottom;">
              <div>By:</div>
            </td>
            <td style="width: 39%; border-bottom: 2px solid rgb(0, 0, 0); text-align: left; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div>/s/ Mondher MAHJOUBI</div>
            </td>
            <td style="width: 5%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 6%;">
              <div>Name:</div>
            </td>
            <td style="width: 39%;">
              <div>Mondher MAHJOUBI</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 6%;">
              <div>Title:</div>
            </td>
            <td style="width: 39%;">
              <div>
                <div>
                  <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Chairman of the Executive Board and Chief Executive Officer</div>
                </div>
              </div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <br>
  </div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a53407863ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR&#8217;579 / IPH6101 in R/R AML</b> </h1>
      <div class="bw-release-subhead">
        <ul style="list-style-type: disc;">
          <b>
            <li> <b><i>SAR&#8217;579/IPH6101, ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> platform lead asset, is a trifunctional anti-CD123 NKp46&#215;CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi</i></b> </li>
            <li> <b><i>Preliminary data published show SAR&#8217;579 was well tolerated and induced 3 complete responses in the 8 patients at 1 mg/kg as highest dose</i></b> </li>
            <li> <b><i>Phase 1/2 data will be presented as an oral presentation at the ASCO 2023 Annual Meeting</i></b> </li>
            <li> <b><i>The study will now progress to the expansion phase</i></b> </li>
          </b>
        </ul>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>MARSEILLE, France--(BUSINESS WIRE)--May 26, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (&#8220;<b>Innate</b>&#8221; or the &#8220;<b>Company</b>&#8221;) announced today that the abstract entitled &#8220;A first-in-human study of CD123 NK Cell Engager
            SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia&#8221; was published on the ASCO 2023 Annual Meeting website. The abstract concludes that SAR&#8217;579, in development by Sanofi,
            was well tolerated up to doses of 3 mg/kg QW with observed clinical benefit in patients with relapsed/refractory acute myeloid leukaemia (R/R AML). </p>
          <p> &#8220;<i>We are very pleased to see in this dose escalation Phase 1/2 update reported by Sanofi, the first clinical responses and good tolerability for SAR&#8217;579/IPH6101 targeting CD123 in relapsed/refractory acute myeloid leukaemia</i>,&#8221; said <b>Mondher
              Mahjoubi, Chief Executive Officer of Innate Pharma</b>. &#8220;<i>Although the data are preliminary, the clinical data from SAR&#8217;579 are encouraging, and we look forward to the full presentation of this trial at the 2023 ASCO Annual Meeting, as well
              as further updates as other assets of our ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> platform enter the clinic</i>.&#8221; </p>
          <p> &#8220;<i>The NK cell engager SAR&#8217;579, targeting CD123 is a remarkably designed investigational drug based on the ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> platform and the result of a strong partnership between Sanofi and Innate scientists</i>,&#8221; adds <b>Valeria Fantin,
              Global Head of Oncology Research at Sanofi</b>. </p>
          <p> &#8220;<i>It is exciting to see these early clinical results at the 2023 ASCO meeting</i>,&#8221; said <b>Peter. C. Adamson, MD, Global Head, Oncology Development at Sanofi</b>. &#8220;<i>We look forward to the continued development of SAR&#8217;579 and are
              thankful to the investigators leading the clinical effort and the patients/families who have volunteered to participate in this trial.&#8221;</i> </p>
          <p> <b>ASCO abstract presentation details:</b> </p>
          <p> <b><u>SAR&#8217;579 / IPH6101</u></b> </p>
          <ul style="list-style-type: disc;">
            <li> <b>Abstract:</b> 7005 </li>
            <li> <b>Abstract Title:</b> A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. </li>
            <li> <b>Session Type/Title:</b> Oral Abstract Session - Hematologic Malignancies &#8211; Leukemia, Myelodysplastic Syndromes, and Allotransplant </li>
            <li> <b>Session Date and Time:</b> 6/2/2023, 1:00 PM - 4:00 PM
              <ul style="list-style-type: circle;">
                <li> <b>Actual Presentation Time: </b>2:24 PM - 2:36 PM </li>
              </ul>
            </li>
          </ul>
          <p> <b>About ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></b> </p>
          <p> ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (<b>A</b>ntibody-based <b>NK</b> cell <b>E</b>ngager <b>T</b>herapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
          </p>
          <p> This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>About the Innate-Sanofi agreement:</b> </p>
          <p> The Company has a research collaboration and licensing agreement with Sanofi to apply Innate&#8217;s proprietary technology to the development of innovative multi-specific antibody formats engaging NK cells through the activating receptors NKp46
            and CD16 to kill tumor cells. </p>
          <p> Under the terms of the 2016 research collaboration and licensing agreement, Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration, which includes IPH6101/SAR&#8217;579
            (CD123 NK Cell Engager) and IPH6401/SAR&#8217;514 (BCMA NK Cell Engager). Innate Pharma will be eligible to up to &#8364;400m in development and commercial milestone payments as well as royalties on net sales. </p>
          <p> Under the terms of a new license agreement entered in December 2022, which includes IPH62 (B7-H3 NK Cell Engager) and 2 options, Innate received &#8364;25m upfront payment and is eligible for up to &#8364;1.35bn total in preclinical, clinical, regulatory
            and commercial milestones plus royalties on potential net sales. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. </p>
          <p> <b>About Innate Pharma</b> </p>
          <p> Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (<b>A</b>ntibody-based
            <b>NK</b> cell <b>E</b>ngager <b>T</b>herapeutics) proprietary platform. </p>
          <p> Innate&#8217;s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
            multi-specific NK cell engagers to address multiple tumor types. </p>
          <p> Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. </p>
          <p> Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. </p>
          <p> Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn. </p>
          <p> <b>Information about Innate Pharma shares</b> </p>
          <table cellspacing="0" id="z60fc6eaab50c445d8ff2db692e61a41c" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>ISIN code </b><br>
                    <b>Ticker code </b><br>
                    <b>LEI</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> FR0010331421 </p>
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Euronext: IPH Nasdaq: IPHA </p>
                  <p style="margin-bottom: 0px; margin-top: 0px;"> 9695002Y8420ZB8HJE29 </p>
                </td>
              </tr>

          </table>
          <p> <b>Disclaimer on forward-looking information and risk factors</b> </p>
          <p> This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and
            similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which
            could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results
            from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts and the Company&#8217;s continued ability to raise capital to fund
            its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please
            refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or on Innate Pharma&#8217;s
            website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the
            AMF or SEC, or otherwise made public, by the Company. </p>
          <p> This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b><u>Investors </u></b><br>
            <b>Innate Pharma </b><br>
            Henry Wheeler <br>
            Tel.: +33 (0)4 84 90 32 88 <br>
            Henry.wheeler@innate-pharma.fr<br>
            <br>
            <b><u>Media Relations </u></b><br>
            <b>NewCap </b><br>
            Arthur Rouill&#233; <br>
            Tel.: +33 (0)1 44 71 00 15 <br>
            innate@newcap.eu </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
